A non-interventional study to assess the long-term safety

Recruiting

99 years or below

All

1 Location

Brief description of study

To document the long-term safety and tolerability profile of osilodrostat in routine clinical practice over a 3 year follow up period in patients with endogenous Cushing's Syndrome. The study population is male and females 18 years or greater who are being treated with osilodrostat.The primary data source will be the medical record of each subject and will be recorded in the eCRF, including physical exam and data from routine visit including patient related outcome questionnaires (PROs).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 14 Jun 2023. Study ID: 853496

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A non-interventional study to assess the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing's syndrome

Brief description of study

Eligibility of study

Find a site

Interested in the study